Status:
COMPLETED
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers
Lead Sponsor:
Arcus Biosciences, Inc.
Conditions:
Cancer
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to determine the safety and tolerability of AB801, and to understand the pharmacokinetic (PK) profile of AB801 when taken as a capsule and tablet in healthy volunt...
Eligibility Criteria
Inclusion
- Key
- Healthy as determined by medical evaluation by study physician
- Body mass index (BMI) of 18.0 to 32.0 kilogram (kg)/meter (m)\^2 as measured at screening
- Weight ≥ 50 kg at screening
- Must agree to adhere to the protocol defined contraception requirements
- Key
Exclusion
- Do not have suitable veins for multiple venepunctures/cannulation as assessed by the study physician
- Prolonged QT interval defined as mean Corrected QT interval by Fridericia's formula (QTcF) ≥ 450 msec for males and \> 470 millisecond (msec) for females at screening and pre-dose
- Clinically significant abnormal clinical chemistry, haematology or urinalysis as judged by the study physician
- Received any study medicine in a clinical research study within the last 90 days
- Taking, or have taken, any prescribed or over-the-counter drugs including gastric acid reducing agents and including CYP3A inhibitor and/or inducers
- Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Key Trial Info
Start Date :
October 16 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 23 2024
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT06004921
Start Date
October 16 2023
End Date
February 23 2024
Last Update
August 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Quotient Sciences - Nottingham
Nottingham, United Kingdom